Jianda Biotechnology

Jianda Biotechnology, officially known as Jianda Fuda Biotechnology (Nanjing) Co., Ltd., is a biopharmaceutical entity established in 2018. The company was founded by a collective of experts with domestic and international experience in vaccine research and development, industrialization, and commercialization, alongside professionals from the pharmaceutical industry. Headquartered in the Biomedical Valley of Nanjing's Jiangbei New Area, Jianda Biotechnology is focused on the development and industrialization of innovative human vaccines and cancer therapeutics.

The company's core activities are driven by its proprietary technology platforms. Jianda has developed a DC-targeting VLP vaccine technology platform and a circular mRNA vaccine technology platform, both of which are protected by independent intellectual property rights. Leveraging these platforms, the company is advancing a pipeline of products. Among its key assets are a recombinant herpes zoster vaccine and a recombinant influenza vaccine. The firm's product pipeline also includes therapeutic vaccines targeting neoplasms and skin diseases, such as the NY-ESO-1 targeted tumor vaccine.

Jianda Biotechnology operates on a business model centered around the research, development, and subsequent commercialization of its biopharmaceutical products. The company's strategy involves progressing its internally developed assets through preclinical and clinical stages to eventually bring them to market. This approach is supported by a series of successful financing rounds. In 2021, the company secured a 33 million RMB angel round from Shenzhen Songshan Venture Capital and Dongguan Juying Investment. More recently, in January 2025, Jianda completed a 50 million RMB Pre-A financing round led exclusively by H鼎 Investment, a notable investor in the biomedical field. This capital is earmarked for advancing the innovative adjuvant shingles vaccine into Phase I-II clinical trials and for the clinical declaration of the recombinant influenza vaccine.

Keywords: vaccine development, cancer therapeutics, biopharmaceutical, DC-targeting VLP, circular mRNA, recombinant herpes zoster vaccine, recombinant influenza vaccine, NY-ESO-1, preclinical development, clinical trials, angel funding, Pre-A financing, Nanjing, biomedical valley, immunotherapy, drug development, life sciences, biotechnology, pharmaceutical industry, therapeutic vaccines